Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Common Equity (2021 - 2025)

Verrica Pharmaceuticals has reported Common Equity over the past 5 years, most recently at $24.7 million for Q4 2025.

  • Quarterly results put Common Equity at $24.7 million for Q4 2025, up 350.94% from a year ago — trailing twelve months through Dec 2025 was $24.7 million (up 350.94% YoY), and the annual figure for FY2025 was $24.7 million, up 350.94%.
  • Common Equity for Q4 2025 was $24.7 million at Verrica Pharmaceuticals, up from -$17.0 million in the prior quarter.
  • Over the last five years, Common Equity for VRCA hit a ceiling of $64.8 million in Q1 2023 and a floor of -$34.1 million in Q3 2024.
  • Median Common Equity over the past 5 years was $25.1 million (2022), compared with a mean of $20.6 million.
  • Peak annual rise in Common Equity hit 350.94% in 2025, while the deepest fall reached 1331.83% in 2025.
  • Verrica Pharmaceuticals' Common Equity stood at $32.6 million in 2021, then rose by 22.78% to $40.0 million in 2022, then tumbled by 50.63% to $19.8 million in 2023, then tumbled by 149.89% to -$9.9 million in 2024, then soared by 350.94% to $24.7 million in 2025.
  • The last three reported values for Common Equity were $24.7 million (Q4 2025), -$17.0 million (Q3 2025), and -$17.5 million (Q2 2025) per Business Quant data.